BMRN Biomarin Pharmaceutical Inc

USD 87.34 -1.27 -1.433247
Icon

Biomarin Pharmaceutical Inc (BMRN) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 87.34

-1.27 (-1.43)%

USD 16.06B

1.03M

USD 103.70(+18.73%)

USD 97.50 (+11.63%)

Icon

BMRN

Biomarin Pharmaceutical Inc (USD)
COMMON STOCK | NSD
USD 87.34
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 16.06B

USD 97.50 (+11.63%)

USD 87.34

Biomarin Pharmaceutical Inc (BMRN) Stock Forecast

Show ratings and price targets of :
USD 103.70
(+18.73%)

Based on the Biomarin Pharmaceutical Inc stock forecast from 9 analysts, the average analyst target price for Biomarin Pharmaceutical Inc is USD 103.70 over the next 12 months. Biomarin Pharmaceutical Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Biomarin Pharmaceutical Inc is Bullish , which is based on 10 positive signals and 4 negative signals. At the last closing, Biomarin Pharmaceutical Inc’s stock price was USD 87.34. Biomarin Pharmaceutical Inc’s stock price has changed by +3.84% over the past week, -1.20% over the past month and -4.48% over the last year.

No recent analyst target price found for Biomarin Pharmaceutical Inc
No recent average analyst rating found for Biomarin Pharmaceutical Inc

Company Overview Biomarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A,...Read More

https://www.biomarin.com

770 Lindaro Street, San Rafael, CA, United States, 94901

3,401

December

USD

USA

Adjusted Closing Price for Biomarin Pharmaceutical Inc (BMRN)

Loading...

Unadjusted Closing Price for Biomarin Pharmaceutical Inc (BMRN)

Loading...

Share Trading Volume for Biomarin Pharmaceutical Inc Shares

Loading...

Compare Performance of Biomarin Pharmaceutical Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for BMRN

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Biomarin Pharmaceutical Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc +0.69 (+0.17%) USD107.38B 29.93 21.06

ETFs Containing BMRN

Symbol Name BMRN's Weight Expense Ratio Price(Change) Market Cap
PBE
Invesco Dynamic Biotechno.. 4.68 % 0.58 % -0.42 (-0.64%) USD0.24B

Frequently Asked Questions About Biomarin Pharmaceutical Inc (BMRN) Stock

Based on ratings from 9 analysts Biomarin Pharmaceutical Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bullish . The stock has 8 buy, sell and 3 hold ratings.

Unfortunately we do not have enough data on BMRN's stock to indicate if its a good dividend stock.

Based on targets from 9 analysts, the average taret price for BMRN is USD 103.70 over the next 12 months. The maximum analyst target price is USD 125 while the minimum anlayst target price is USD 82.

BMRN stock's Price/Earning ratio is 97.85. Our analysis grades BMRN stock's Price / Earning ratio at F. This means that BMRN stock's Price/Earning ratio is above 91% of the stocks in the Biotechnology sector in the NSD exchange. Based on this BMRN may be a overvalued for its sector.

The last closing price of BMRN's stock was USD 87.34.

The most recent market capitalization for BMRN is USD 16.06B.

Based on targets from 9 analysts, the average taret price for BMRN is projected at USD 103.70 over the next 12 months. This means that BMRN's stock price may go up by +18.73% over the next 12 months.

Following are ETFs with the highest allocation to Biomarin Pharmaceutical Inc's stock :

PBE

As per our most recent records Biomarin Pharmaceutical Inc has 3,401 Employees.

Biomarin Pharmaceutical Inc's registered address is 770 Lindaro Street, San Rafael, CA, United States, 94901. You can get more information about it from Biomarin Pharmaceutical Inc's website at https://www.biomarin.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...